Concarlo Therapeutics
www.concarlo.comFounded in July 2016 and headquartered in Brooklyn, New York, Concarlo is a precision-medicine oncology company focused on diagnosing and treating cancer with an innovative approach to targeting a unique cellular pathway - p27Kip1. Concarlo's novel IpY therapeutic will be the first inhibitor to solve the CDK2 resistance issue, the first therapeutic to target p27 and the first to inhibit CDK4 and CDK2 simulataneously.
Read more
Founded in July 2016 and headquartered in Brooklyn, New York, Concarlo is a precision-medicine oncology company focused on diagnosing and treating cancer with an innovative approach to targeting a unique cellular pathway - p27Kip1. Concarlo's novel IpY therapeutic will be the first inhibitor to solve the CDK2 resistance issue, the first therapeutic to target p27 and the first to inhibit CDK4 and CDK2 simulataneously.
Read more
Country
State
New York
City (Headquarters)
Brooklyn
Industry
Employees
1-10
Founded
2016
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Development Officer
Email ****** @****.comPhone (***) ****-****Co - Founder , Chief Scientific Officer , and Acting Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Executive Chairman
Email ****** @****.comPhone (***) ****-****Business Advisory Board Member
Email ****** @****.comPhone (***) ****-****
Technologies
(16)
